In conclusion, we demonstrate that inhibition of BRD4 suppresses APT1 expression and subsequently promotes MST1 palmitoylation and blocks the nuclear translocation of YAP1, thereby sensitizing NSCLC cells to osimertinib. This evidence concerns the gene LYPLA1 and non-small cell lung carcinoma.